氯雷他定糖漿市場：現狀分析與預測（2022-2030）

氯雷他定糖漿市場因其商業化、安全性高、處方不昏昏等特點受到各年齡段消費者的青睞，預計將穩定增長在2%左右。 此外，人們對過敏及其對健康的影響、城市化、導致接觸過敏原的環境因素等的認識不斷提高，正在推動對氯雷他定糖漿市場的需求。

市場按年齡分為成人產品和兒童產品。 在預測期內，兒科類別將表現出更高的複合年增長率。 這主要是由於兒童過敏和花粉熱的高發病率、對兒童安全藥物的考慮以及長效製劑。 例如，2021年，美國約有8100萬人被診斷患有季節性過敏性鼻炎（花粉症）。 這相當於大約 26% 的成年人（6700 萬人）和 19% 的兒童（1400 萬人）。

根據適應症，市場分為過敏性鼻炎和蕁麻疹。 其中，過敏性鼻炎在2021年佔據了很大的市場份額。 這主要是由於政府機構投資和資助活動的增加以及全球過敏性鼻炎患病率的上升。 例如，根據美國國立衛生研究院 (NIH) 的數據，大約 3.39 億人患有哮喘，2 億至 2.5 億人患有食物過敏，4 億人患有鼻炎。

根據藥物類型，氯雷他定糖漿市場分為品牌藥和仿製藥。 在預測期內，氯雷他定糖漿的高采用率將屬於品牌產品類別。 這主要是因為藥企在營銷和品牌上投入了大量資金，而且忠誠度很高。 此外，品牌藥物通常是第一個進入市場的版本，並且這個特定版本已經過仔細的測試，以向消費者保證其有效性。

為了更好地了解氯雷他定糖漿行業的市場介紹，將市場分為北美（美國、加拿大和北美其他地區）、歐洲（德國、英國、法國、西班牙、意大利和其他地區）歐洲） 、亞太地區（中國、日本、印度、亞太其他地區）和世界其他國家。 預計北美在預測期內將以顯著的複合年增長率增長。 由於該地區人口眾多、城市化和工業化程度較高，過敏病例不斷增加。 由於環境因素，亞太地區過敏性鼻炎的患病率也很高。 例如，根據國家醫學圖書館 (NLM) 發表的一篇論文，印度人口超過 13.5 億，佔世界人口的近 20%。 在慢性病中，過去幾年，過敏性鼻炎（AR）和哮喘等過敏性疾病在印度似乎呈上升趨勢。 目前該地區大約 22% 的成年人患有過敏性鼻炎 (AR)。 因此，對氯雷他定糖漿等有效的過敏緩解藥物的需求不斷增長。 在中國、印度和日本等國家，不斷壯大的中產階級、不斷上漲的醫療成本以及不斷改善的醫療基礎設施正在推動市場增長。 此外，在亞太地區的幾個國家，氯雷他定糖漿作為非處方藥出售，使消費者可以輕鬆獲得。

目錄

第一章市場介紹

• 市場定義
• 主要目的
• 利益相關者
• 限制

第二章研究方法或假設

• 調查過程
• 調查方法
• 受訪者簡介

第三章市場總結

第 4 章執行摘要

第五章 COVID-19 對氯雷他定糖漿市場的影響

第 6 章 2020-2030 年氯雷他定糖漿市場收入

第 7 章按年齡劃分的市場洞察

• 成人使用
• 兒童

第 8 章按指標劃分的市場洞察

• 過敏性鼻炎
• 蕁麻疹

第 9 章按藥品類型劃分的市場洞察

• 品牌
• 通用

第 10 章按地區劃分的市場洞察

• 北美
  • 美國
  • 加拿大
  • 其他北美地區
• 歐洲
  • 德國
  • 英國
  • 法國
  • 意大利
  • 西班牙
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 其他亞太地區
• 世界其他地區

第11章氯雷他定糖漿市場動態

• 市場驅動因素
• 市場挑戰
• 影響分析

第12章氯雷他定糖漿市場機會

第13章氯雷他定糖漿市場趨勢

第14章需求側和供給側分析

• 需求方分析
• 供給側分析

第 15 章價值鏈分析

第16章價格分析

第 17 章戰略洞察

第18章競爭場景

• 競爭狀況
  • 波特五力分析

第19章公司簡介

• Merck KGaA
• Cadila Pharmaceuticals
• Medico Remedies Limited
• Sun Pharmaceutical Industries Ltd.
• GSK plc.
• Perrigo Company plc,
• Novartis AG
• Taro Pharmaceutical Industries Ltd.
• Dr. Reddy's Laboratories Ltd.
• Bayer Inc.

第20章 免責事項

Loratadine syrup is a medication used to provide relief from allergy symptoms. This is known for its non-drowsy formula, making it suitable for daytime use without causing significant sedation. It effectively alleviates symptoms like sneezing, runny nose, itching, and watery eyes associated with allergies, providing long-lasting relief. The syrup formulation offers convenience, particularly for pediatric populations or individuals who have difficulty swallowing pills, as it allows for easy administration and accurate dosing. The loratadine syrup market is experiencing steady growth and is driven by several key factors such as the increasing prevalence of allergies, such as seasonal allergies, hay fever, and allergic rhinitis, which has fueled the demand for loratadine syrup. For instance, according to an article published by a U.S. organization, 339 million are suffering from asthma, 200 to 250 million have a food allergy and 400 million have rhinitis globally.

The loratadine syrup market is expected to grow at a steady rate of around 2% owing to Its over-the-counter availability, favorable safety profile, and non-drowsy formula making it a preferred choice for consumers across different age groups. Moreover, the growing awareness about allergies and their impact on health, coupled with the urbanization and environmental factors contributing to allergen exposure, has bolstered the market demand for loratadine syrup.

Based on age, the market is segmented into adult and pediatric. The pediatric category is to witness a higher CAGR during the forecast period. This is mainly due to the high prevalence of allergies and hay fever in children, consider a safe medication for children and long-acting formulations. For instance, in 2021, around 81 million people in the U.S. were diagnosed with seasonal allergic rhinitis (hay fever). This equals around 26% (67 million) of adults and 19% (14 million) of children.

On the basis of indication, the market is categorized into allergic rhinitis and urticaria. Among these, allergic rhinitis held a significant share of the market in 2021. This is mainly due to the growing investment & funding activities by government bodies and the rising prevalence of allergic rhinitis all over the world. For instance, as per the National Institutes of Health (NIH), around 339 million are suffering from asthma, 200 to 250 million have a food allergy and 400 million have rhinitis globally.

Based on drug type, the loratadine syrup market has been classified into branded and generic. The branded category is to witness higher adoption of loratadine syrup during the forecast period. This is mainly due to the pharmaceutical companies spending on marketing & branding and their loyalty being higher. Also, brand-name pills are usually the first version of the drug on the market, and this specific version has undergone careful testing to ensure efficacy to consumers.

For a better understanding of the market adoption of the loratadine syrup industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is anticipated to grow at a substantial CAGR during the forecast period. the large population, coupled with increasing urbanization and industrialization, has led to a rise in allergy cases in the region. APAC also experiences a higher prevalence of allergic rhinitis due to environmental factors. For instance, as per an article published by the National Library of Medicine (NLM), with more than 1.35 billion people, India is home to nearly 20% of the global population. Of all chronic diseases, allergic diseases such as allergic rhinitis (AR) and asthma seem to increase in India over the past few years. Approximately, 22% of adults at present experience allergic rhinitis (AR) in the region. As a result, there is an increasing demand for effective allergy relief medications like loratadine syrup. The growing middle class, rising healthcare expenditure, and improving healthcare infrastructure in countries like China, India, and Japan contribute to the market growth. Additionally, the availability of loratadine syrup as an OTC medication in several countries within the APAC region makes it easily accessible to consumers.

Some of the major players operating in the market include: Merck KGaA; Cadila Pharmaceuticals; Medico Remedies Limited; Sun Pharmaceutical Industries Ltd.; GSK plc.; Perrigo Company plc; Novartis AG; Taro Pharmaceutical Industries Ltd.; Dr. Reddy's Laboratories Ltd.; and Bayer Inc.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Loratadine Syrup Market
• 2.2. Research Methodology of the Loratadine Syrup Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE LORATADINE SYRUP MARKET

6 LORATADINE SYRUP MARKET REVENUE, 2020-2030F

7 MARKET INSIGHTS BY AGE

• 7.1. Adult
• 7.2. Pediatric

8 MARKET INSIGHTS BY INDICATION

• 8.1. Allergic Rhinitis
• 8.2. Urticaria

9 MARKET INSIGHTS BY DRUG TYPE

• 9.1. Branded
• 9.2. Generic

10 MARKET INSIGHTS BY REGION

• 10.1. North America
  • 10.1.1. U.S.
  • 10.1.2. Canada
  • 10.1.3. Rest of North America
• 10.2. Europe
  • 10.2.1. Germany
  • 10.2.2. U.K.
  • 10.2.3. France
  • 10.2.4. Italy
  • 10.2.5. Spain
  • 10.2.6. Rest of Europe
• 10.3. Asia-Pacific
  • 10.3.1. China
  • 10.3.2. Japan
  • 10.3.3. India
  • 10.3.4. Rest of Asia-Pacific
• 10.4. Rest of World

11 LORATADINE SYRUP MARKET DYNAMICS

• 11.1. Market Drivers
• 11.2. Market Challenges
• 11.3. Impact Analysis

12 LORATADINE SYRUP MARKET OPPORTUNITIES

13 LORATADINE SYRUP MARKET TRENDS

14 DEMAND AND SUPPLY-SIDE ANALYSIS

• 14.1. Demand Side Analysis
• 14.2. Supply Side Analysis

15 VALUE CHAIN ANALYSIS

16 PRICING ANALYSIS

17 STRATEGIC INSIGHTS

18 COMPETITIVE SCENARIO

• 18.1. Competitive Landscape
  • 18.1.1. Porters Fiver Forces Analysis

19 COMPANY PROFILED

• 19.1. Merck KGaA
• 19.2. Cadila Pharmaceuticals
• 19.3. Medico Remedies Limited
• 19.4. Sun Pharmaceutical Industries Ltd.
• 19.5. GSK plc.
• 19.6. Perrigo Company plc,
• 19.7. Novartis AG
• 19.8. Taro Pharmaceutical Industries Ltd.
• 19.9. Dr. Reddy's Laboratories Ltd.
• 19.10. Bayer Inc.

20 DISCLAIMER